Aerovate Therapeutics(AVTE) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights ● Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) ● Enrollment continues into the Phase 3 portion of the IMPAHCT trial of AV-101 ● Poster to be presented with baseline characteristics of the Phase 2b portion of the IMPAHCT trial at the ATS 2024 Conference on May 21 ● Cash runway into 2026, based ...